ReviewThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials.
Review in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperlipidemia is a common condition as nearly over 50% of adult Americans have high low-density lipoprotein (LDL) levels. Hyperlipidemia increases the risk of strokes, myocardial infarction, and other vascular events. PCSK9 monoclonal antibodies are one of the available options for the treatment of hyperlipidemia. Our study is a systematic review and meta-analysis that assesses the efficacy and safety of a new PCSK9 antibody, tafolecimab, in hyperlipidemia.
methodsSearching PubMed, EMBASE, Scopus, Web of Science (WOS), and Cochrane, we performed a PRISMA-based systematic review and meta-analysis to study effects of tafolecimab compared with placebo on different lipid indices that included LDL percent change, number of patients achieving ≥ 50% low-density lipoprotein cholesterol (LDL-C) reduction, LDL change from baseline, LDL change from baseline (CFB), apolipoprotein B CFB, and non-high-density lipoprotein cholesterol (non-HDL-C) CFB.
resultsFour randomized controlled trials (RCTs) with 1093 patients were included in our study; 709 (64.87%) of them were males. Tafolecimab reduced LDL percent change [mean difference (MD) = - 62.28, 95% confidence interval (CI) (- 65.21, -59.35), P < 0.00001], the number of patients achieving ≥ 50% LDL-C reduction [MD = 46.92, 95% CI (21.91, 103.9), P < 0.0001], LDL CFB [MD = - 73.58, 95% CI (- 83.13, -64.03), P < 0.001], non-HDL-C CFB [MD = - 82.21, 95% CI (- 86.65, - 77.77), P < 0.001], apolipoprotein B CFB [MD = - 52.01, 95% CI (- 54.86, - 49.17, P < 0.001]. No difference was detected in overall adverse events (AEs) [risk ratio (RR) = 0.94, 95% CI (0.88, 1.01), P = 0.1128], serous AEs [RR = 0.93, 95% CI (0.57, 1.52), P = 0.7799], and AEs leading to treatment discontinuation [RR = 2.58, 95% CI (0.76, 8.77), but yielded more injection site reactions [RR = 2.53, 95% CI (1.14, 5.63), P = 0.0222].
conclusionTafolecimab is a valuable treatment option for hyperlipidemia, which showed improvement in several lipid indices (LDL, LDL-C, LDL CFB, non-HDL-C CFB, and apolipoprotein B CFB). However, it increased the rates of injection site reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.